We are proud to announce that Drug Combination Detection (DCT) has just landed in our infrastructure. Next corpora updates will have the feature enabled by default, unlocking a big milestone in systematic drug-drug interaction illumination in Real Word Evidence (RWE) datasets like FDA Adverse Event Reporting System (FAERS) or ClinicalTrials.gov (CTGov).
In many contexts, drugs are mentioned in combination because they are co-administrated. These combinations may be referred to either by using active ingredient names, or synonyms or product (brand) names, resulting in inconsistent nomenclature. In addition, the order by which the ingredients are listed is not standardized. Furthermore some drug combinations often reflect off-label co-administration, while others arise from independent prescribing decisions or coincidental concurrent use, rather than representing established combination therapies.
Our system successfully detects a lot of corner cases as drug combinations that were previously undetected, thus enriching the dataset where combinations occur leading to more accurate detection of actionable signals. By capturing previously overlooked drug combinations, it provides a more complete and standardized representation of real-world regimens improving the identification of signals related to therapeutic efficacy and drug-drug interactions. This also supports more accurate patient stratification and facilitates personalized medicine, by enabling treatment decisions tailored to individual patient needs.
Stay tuned for the next update.